Ad
related to: new bipolar depression medication resistant to alcohol abuse treatment
Search results
Results from the WOW.Com Content Network
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2] It is developed by Intra-Cellular Therapies, licensed from Bristol ...
Cariprazine is used to treat patients with schizophrenia and manic, depressive, or mixed episodes associated with bipolar I disorder.In the United States it is approved for schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and treatment of depressive episodes associated with bipolar I disorder (bipolar depression).
Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. [1] In 2009, it was granted approval for the treatment of treatment-resistant depression.
Duloxetine is one of the most commonly used prescription medications in the U.S. Patients with depression are usually prescribed 40 to 60 milligrams per day, with a potential increase of up to 120 ...
In a single controlled study of twenty one patients, the dopamine D 3 receptor agonist pramipexole was found to be highly effective in the treatment of bipolar depression. Treatment was initiated at 0.125 mg thrice daily and increased at a rate of 0.125 mg thrice daily to a limit of 4.5 mg per day until the patients' condition satisfactorily ...
Lurasidone, sold under the brand name Latuda among others, is an atypical antipsychotic medication used to treat schizophrenia and bipolar depression. [2] It is taken by mouth. Common side effects include sedation, indigestion, nausea, and insomnia. At higher dosages, there is an increased risk for restlessness and mild movement problems. [2]
At least five atypical antipsychotics (lumateperone, [48] cariprazine, [49] lurasidone, [50] olanzapine, [51] and quetiapine [52]) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine [53] and quetiapine [54] [55] have been proven to be effective broad-spectrum (i.e., against ...
Maprotiline is used in the treatment of depression, such as depression associated with agitation or anxiety and has similar efficacy to the antidepressant drug moclobemide. [12] This finding has also been validated by a group of general practitioners who compared the respective efficacy and tolerability of maprotiline and moclobemide. [13]
Ad
related to: new bipolar depression medication resistant to alcohol abuse treatment